Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And acst also had a move a few days AGO.
ACST has also moved 80 percent today. On huge volume.
So if my H20 is processed through a de-ionizing system, is it still the same H20 as yours?
I think the statement on the Limitations page is key for Vascepa. "Results only apply to this specific icosapent ethyl formulation of EPA". Amarin needs to differentiate V from gV, then convince the FDA that is a relevant and signification difference.
I wonder if the author has experience with other brands or formulations of epa?
Need an analyst to ask what Hikma is estimating for upcoming generic Vascepa sales. If significantly reduced from last year's estimate, need an analyst to ask why the difference. Amarin needs to make sure they have a friendly analyst at the event.
I recall seeing the video you are referring to. A board member shared the link about a year ago. If u search YouTube by bhatt nissen u will see a series of videos entitled HCPLive Exchange. I believe it Is within one of these. Went through those quickly, did not find the bit u mentioned. Nissen is somewhat annoying on each video, does majority of talking.
You may be right. He will have to clarify. I do recall, prior to Du verdict, that BB was calling for a >$100 buyout, and had mentioned a $200 value. HDGabor also speculated high 2 figure, possibly low 3 figure price. At this point, I am hoping for 30-40 after europe approval, so my read may be biased.
I agree. Only way to meet all demand being speculated on this board. I would also think a unique formulation is the best way to fend off the generics.
I assumed that the other way, 2 amrn for 1 gild. gild at $60.76 right now. Do not see us getting a $120/share buyout. Unless the $150 ask that ihub has had up all weekend is an true indicator.
Israel? Based on your comments I assumed you were an American lawyer.
I thought his comment regarding the stickiness of the generic was interesting. Oil leaching through the capsule? Or, oxidated oil affecting the capsule? Since it is generic, probably just cheaper material, or processing, used for the capsule
I cannot say I have been symptom free of colds and flus. But when family or work office have had issues, I have been ok or had much less severity.
The case has not had a trial, appeal or en bank. Reduce-It was not discussed during the previous patent trial.
gV's total scripts is greater than new scripts. The difference is for refills? Has gV been on the market long enough to have refills? Even if every script was for 30 day supply? Or are those refills based off an original V script?
If it is oxidized, I assume the chemical composition also changes. Would that mean the gV is not a bioidentical composition? I would hope the FDA would then be forced to halt gV sales.
It is found in Section 3 of the MSDS. However, defined as 60%-80% of 1000mg capsule. The two other ingredients can be 10%-25% of the capsule.
A study similar to what MTNB is doing, comparing their O3 drug to Vascepa? I am assuming it would be a 12 week test for high trigs. The risk would be gV shows statistically similar results to V.
My family has had issues with generic thyroid medication. We could see and feel the inconsistencies from script to script. My doctor had similar stories for her own scripts. The retailer also has some responsibility edibility for script variation by using more than one generic supplier for a drug, resulting in more variation.
After going through our experiences with V, I would say the FDA and Congress are not making generic equivalency a priority. Simply a numbers game for political purposes.
Do any of these generic companies have American production facilities?
I assumed that was a standard bot reply to any medication questions.
I wrote express scripts about my V prescription and generic Hikma. This was the repky:
, Thank you for your online inquiry. I understand your concern with your prescription. I will be happy to assist you with coverage information. I have run a coverage check for Vascepa. Please be advised that currently there is no direct generic version of this medication available. Please speak with your physician regarding alternative medication options.
I thought writing on the wall, or laid off, first. Not buy out.
I heard that guy was banned from visiting Alaska. He was scaring the bears.
Can you provide a link to pr you are referring to? I could not find anything on yahoo, google or hikma website with any news.
Wow, hockey stick numbers.
If the doctor does not know how to pronounce the name of the product, then there is an education and marketing issue that management needs to address immediately within the professional medical field. Annoying to listen to him say, then say an alternate pronunciation, each time he referred to Vascepa.
Marketing seems to be a stumbling block for this management team. Sales up 20-30% y/y, but we have never seen that hockey stick move. Expected more with 800 person sales force. Adds to doubts about GIA in Europe.
I wondered the same thing when I read the 80% statement on this site. I also wonder if the cheaper generic has a fishy aftertaste.
Does it make amrn profitable? That has been a challenge up to this point. Cashflow that pays the salaries and bills is good for employees, not necessarily stockholders.
Anyway to determine if Amarin is charging the wholesaler or retailer the same price? Hate to fine out the price has already been torpedoed to generic levels. I am on IL BCBS, pay $100 for 3 months, got prescription refilled this week. Express Scripts says retail price is $799.99 for 3 months.
And, labels on the 3 bottles I received are the color as all prior orders.
Good article. Be a shame if she is replaced in next few years with a biden choice. Supreme court comments regarding ph, Mn, and Mg, Du's court is not the only one to make mistakes on science. Scary.
Or the price is being walked up in preparation for a sale. Get the price up to an acceptable multiple to the buyer's shareholders.
Contact Elisabeth in IR. She has sent me old versions, promptly.
Internal company announcement to the workforce? Believe u have mentioned a source before.
Wish I had saved the post that had a link that described the en banc process. I recall employment being one of the considerations. Assume the sales force will stay in place until the en banc decision is made. I have not seen a V commercial in a couple weeks.
T'man, thank you for the information every Friday.
So, BBs were also overly confident in the strength of the patents? Held through the price spikes.
Regarding point 2, is it a mathematical mistake, or, a difference in how the FDA and PTO review the data? Seems the emphasis should be on accepted statistical process and conclusion resolution. The presented evidence did not follow accepted american practice, so may not have been given any weight by PTO.
Was Kennedy involved with the process for the Marine patents?
It needs some cleanup, but the thought is there. I can give u my thoughts privately.
I did not expect them to be knowledgable aboutV. But they do medication reviews on patients all day long. I would hope they had heard of the name a time or two in the past year. All 7, same type response, what is it....never heard of it. Would hope they had at least seen commercials.
Thanks, do not feel to bad. Sure I will change my tune in a day or two.. Friends said the first day is a trick. Second day is when the tightness sets in.
At what point did our council have the opportunity to see this cropped table? And the uncropped table?